Popoviciu MS, Pduraru L, Yahya G, Metwally K, Cavalu S (2023) Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials
This conclusion was reached not only because of the subtle increase in exposure but also due to the wide therapeutic index of semaglutide
Many healthcare providers are more familiar with injectable GLP-1 therapies, given their longer history
When they are discontinued: A1C levels often rise Fasting blood sugar may increase Diabetes symptoms may return Thus, for patients with Type 2 diabetes, stopping a GLP-1 without an alternative treatment plan can increase the risk of worsening blood sugar control, making close medical supervision and proactive adjustments essential.2 Digestion Speeds Back Up Once you discontinue a GLP-1, your digestive system returns to its baseline rhythm: Food empties from the stomach more quickly Earlier hunger cues return Cravings may become harder to control Many patients find it helpful to follow structured eating guidance like the one outlined in our nutritional support program
Interestingly, studies examining placental passage of exenatide and liraglutide in human cases suggest minimal to no fetal exposure shortly after administration, indicating that maternal metabolic effects, rather than direct fetal exposure, may contribute to adverse outcomes
